New Thread

Ctrl

I

Response Oncology, Inc. Price: Quote, Forecast, Charts & News (ROIX)

Perplexity Finance

/

Company Profile

Response Oncology, Inc. Price & Performance (ROIX)

Stock Performance

Updated May 15, 2023, 7:31 PM UTC

Response Oncology, Inc.

$0.000001USD

-$0.000009 (-90%)

Open

$0.00

Market Cap

$12.00

Year High

$0.00

High

$0.00

P/E Ratio

-0.0

Year Low

$0.00

Low

$0.00

Dividend Yield

Volume

500.00

What's Happening

Related

Financial information provided by Financial Modeling Prep. Options data provided by Unusual Whales. Live transcripts provided by Quartr. All data is provided for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. · See all tickers.

Overview
Latest News
Earnings
Related

Go Deeper

How might recent FDA rejections of major cancer drug combinations impact investor sentiment toward smaller oncology stocks like Response Oncology, Inc.?
Could the rising trend of big pharma acquiring innovative cancer therapy startups lead to acquisition interest in Response Oncology, Inc.?
What are the potential effects of new FDA-approved cancer therapies on the competitive landscape for Response Oncology, Inc.?
How could recent high-profile clinical trial failures and delays in the oncology sector influence Response Oncology, Inc.'s valuation and funding opportunities?
Are there any upcoming regulatory decisions or clinical trial results that could serve as catalysts for Response Oncology, Inc.'s stock price movement?

Latest News

HUTCHMED Achieves Key Milestone with Savolitinib in Gastric Cancer Trial
Apr 22, 2025
HUTCHMED has completed patient enrollment for its Phase II registration study of savolitinib in MET-amplified gastric cancer. Interim results show a 45% objective response rate and a manageable safety profile. The drug holds Breakthrough Therapy Designation in China, marking a significant step toward potential accelerated approval.1234
Ascentage Pharma's Lisaftoclax and Olverembatinib Win CSCO Guideline Endorsements
Apr 22, 2025
Ascentage Pharma announced that its Bcl-2 inhibitor lisaftoclax and TKI olverembatinib have been included in the 2025 Chinese Society of Clinical Oncology guidelines. Lisaftoclax is now recommended for relapsed/refractory CLL/SLL, while olverembatinib received upgraded guidance for pediatric leukemias, underscoring their growing clinical impact.5
Race Oncology Expands RC220 Solid Tumor Trial to Second Clinical Site
Apr 21, 2025
Race Oncology has activated a second clinical site at Central Coast Local Health District for its Phase 1 trial of RC220 (bisantrene) with doxorubicin in advanced solid tumors. This expansion aims to accelerate patient recruitment and gather vital safety, tolerability, and pharmacokinetic data across multiple Asia-Pacific locations.6